65,437 trials
Hemophilia
Primary: Mean Absolute Values of Anxiety Measured by an Anxiety Visual Analogue Scale (A-VAS) Before Each Factor VIII or Factor IX Infusion in Participants and Caregivers — 0.2…
Breast Cancer
Primary: Progression-free Survival — 4.8; 4.1; 3.5 Months — p=0.76
Intracranial Hemorrhage
Primary: Number of Participants With Modified Rankin Score (mRS) ≤ 3 or mRS > 3 — 17; 20 Participants
Kidney Transplantation
Primary: Number of Patients Alive — 7; 13 Participants
Dry Eye Disease
Primary: University of North Carolina Dry Eye Management Scale (UNC DEMS) Responder Analysis — 53.2; 60.0; 65.2 percentage of responders — p=0.2933
Acute Lymphoblastic Leukemia (ALL)
Primary: Phase 1b: Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs) — 5; 6; 3; 7 Participants
Pulmonary Arterial Hypertension
Primary: Percent Change From Baseline of Pulmonary Vascular Resistance (PVR) at Week 24 — 63.083; 64.219; 5.813 percent — p=0.0208
Metastatic Esophageal Carcinoma · Metastatic Gastric Carcinoma · Metastatic Gastroesophageal Junction Adenocarcinoma
Primary: Dose Limiting Toxicity and Maximum Tolerated Dose of Olaparib (Phase I) — 0; 1 Participants
Pregnancy Related
Primary: Trimester Specific Prothrombin Time Reference Interval — 11.40; 10.60; 10.40 seconds
Plantar Fascitis
Primary: Foot and Ankle Ability Measure (FAAM) — 47.00; 45.28; 11.65; 11.72 Percentage of function
Prostatic Neoplasms
Primary: Duration of Therapy (DOT) — 18.5 Months
Smoking · Smoking Cessation · HIV Infections
Primary: Number of Participants Reporting 7-day Point-prevalence Abstinence — 8; 12; 3; 2 participants
Menopause
Primary: Effect of CE/BZA (TSEC) on Body Composition — 91.3; 90.6; 45.5; 45.7 Kilograms
Lymphoma, Non-Hodgkin · Leukemia, Lymphocytic, B Cell · B-Cell Lymphoma
Primary: Grades of Toxicity by Type of Toxicity — 2; 2; 1; 1 toxicities
Plasma Cell Myeloma
Primary: Proportion of Patients Who Achieve a Confirmed Complete Response (CR) — 0.32; 0.30 proportion of participants